221 related articles for article (PubMed ID: 19190080)
21. Sparing fertility in young patients with endometrial cancer.
Chiva L; Lapuente F; González-Cortijo L; Carballo N; García JF; Rojo A; Gonzalez-Martín A
Gynecol Oncol; 2008 Nov; 111(2 Suppl):S101-4. PubMed ID: 18804267
[TBL] [Abstract][Full Text] [Related]
22. [Two cases of endometrial stromal sarcoma (ESS) in which survival was prolonged by administration of MPA].
Ishibashi M; Nakayama K; Shamima Y; Katagiri A; Iida K; Nakayama N; Miyazaki K
Gan To Kagaku Ryoho; 2008 May; 35(5):857-61. PubMed ID: 18487930
[TBL] [Abstract][Full Text] [Related]
23. Molecule-targeted agents in endometrial cancer.
Delmonte A; Sessa C
Curr Opin Oncol; 2008 Sep; 20(5):554-9. PubMed ID: 19106660
[TBL] [Abstract][Full Text] [Related]
24. [Primary hormone treatment of early endometrial cancer].
Ivanov S; Ivanov S; Kŭrlov T; Milev A; Kulander S; Ivanov V
Akush Ginekol (Sofiia); 1999; 38(1):20-3. PubMed ID: 11965713
[TBL] [Abstract][Full Text] [Related]
25. Apoptosis and colorectal cancer: implications for therapy.
Yang SY; Sales KM; Fuller B; Seifalian AM; Winslet MC
Trends Mol Med; 2009 May; 15(5):225-33. PubMed ID: 19362056
[TBL] [Abstract][Full Text] [Related]
26. Endometrial cancer: reviving progesterone therapy in the molecular age.
Yang S; Thiel KW; De Geest K; Leslie KK
Discov Med; 2011 Sep; 12(64):205-12. PubMed ID: 21955848
[TBL] [Abstract][Full Text] [Related]
27. [Drug resistance mediated by survival- and growth-promoting signaling pathways].
Fujita N
Gan To Kagaku Ryoho; 2009 Apr; 36(4):567-71. PubMed ID: 19381028
[TBL] [Abstract][Full Text] [Related]
28. Mechanisms of apoptosis resistance and treatment strategies to overcome them in hormone-refractory prostate cancer.
Uzzo RG; Haas NB; Crispen PL; Kolenko VM
Cancer; 2008 Apr; 112(8):1660-71. PubMed ID: 18278811
[TBL] [Abstract][Full Text] [Related]
29. Systemic therapy for recurrent endometrial cancer: a review of North American trials.
Dellinger TH; Monk BJ
Expert Rev Anticancer Ther; 2009 Jul; 9(7):905-16. PubMed ID: 19589030
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of estrogen actions in human gynecological malignancies: new aspects of endocrine therapy for endometrial cancer and ovarian cancer.
Ito K; Utsunomiya H; Niikura H; Yaegashi N; Sasano H
Mol Cell Endocrinol; 2011 Jul; 340(2):161-7. PubMed ID: 21111773
[TBL] [Abstract][Full Text] [Related]
31. GnRH-II antagonists induce apoptosis in human endometrial, ovarian, and breast cancer cells via activation of stress-induced MAPKs p38 and JNK and proapoptotic protein Bax.
Fister S; Günthert AR; Aicher B; Paulini KW; Emons G; Gründker C
Cancer Res; 2009 Aug; 69(16):6473-81. PubMed ID: 19638591
[TBL] [Abstract][Full Text] [Related]
32. [Adjuvant therapy and role of radiation therapy in advanced endometrial cancers].
Haie-Meder C; Paumier A; Lessard N; Morice P; Pautier P; Touboul C
Cancer Radiother; 2008 Nov; 12(6-7):630-2. PubMed ID: 18760653
[TBL] [Abstract][Full Text] [Related]
33. Insulin resistance: a significant risk factor of endometrial cancer.
Mu N; Zhu Y; Wang Y; Zhang H; Xue F
Gynecol Oncol; 2012 Jun; 125(3):751-7. PubMed ID: 22449736
[TBL] [Abstract][Full Text] [Related]
34. Biologic markers in endometrial cancer treatment.
Engelsen IB; Akslen LA; Salvesen HB
APMIS; 2009 Oct; 117(10):693-707. PubMed ID: 19775337
[TBL] [Abstract][Full Text] [Related]
35. Adjuvant carboplatin and paclitaxel chemotherapy interposed with involved field radiation for advanced endometrial cancer.
Lupe K; D'Souza DP; Kwon JS; Radwan JS; Harle IA; Hammond JA; Carey MS
Gynecol Oncol; 2009 Jul; 114(1):94-8. PubMed ID: 19406459
[TBL] [Abstract][Full Text] [Related]
36. Human bladder cancer cells undergo cisplatin-induced apoptosis that is associated with p53-dependent and p53-independent responses.
Konstantakou EG; Voutsinas GE; Karkoulis PK; Aravantinos G; Margaritis LH; Stravopodis DJ
Int J Oncol; 2009 Aug; 35(2):401-16. PubMed ID: 19578756
[TBL] [Abstract][Full Text] [Related]
37. Is the cancer stem cell population "a player" in multi-drug resistance?
Drewa T; Styczynski J; Szczepanek J
Acta Pol Pharm; 2008; 65(4):493-500. PubMed ID: 19051593
[TBL] [Abstract][Full Text] [Related]
38. What's new in systemic therapy for endometrial cancer.
Kieser K; Oza AM
Curr Opin Oncol; 2005 Sep; 17(5):500-4. PubMed ID: 16093803
[TBL] [Abstract][Full Text] [Related]
39. Levonorgestrel, medroxyprogesterone and progesterone cause a concentration-dependent reduction in endometrial cancer (Ishikawa) cell density, and high concentrations of progesterone and mifepristone act in synergy.
Moe BT; Vereide AB; Orbo A; Jaeger R; Sager G
Anticancer Res; 2009 Apr; 29(4):1047-52. PubMed ID: 19414344
[TBL] [Abstract][Full Text] [Related]
40. Leuprolide in the treatment of endometrial cancer.
Markman M; Kennedy A; Webster K; Peterson G; Kulp B; Belinson J
Gynecol Oncol; 1997 Sep; 66(3):542. PubMed ID: 9299275
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
